UEG's content platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

UEG Week Berlin 2025 Recordings Gut Guide online What's new on Gutflix

Trending on Gutflix

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Poster

Audio / Video Poster

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

CARDIOVASCULAR RISK IN INDIVIDUALS WITH COELIAC DISEASE IN THE TRØNDELAG HEALTH STUDY (HUNT4)

Stephanie Zühlke 1,2, Rebecka Hjort 1, Marta Riise Moksnes 1, Magnus Nakrem Lyngbakken 3,4, Mohammad Sayeef Alam 1, Anne Kristin Aksaas 5, Ingrid Løvold Mostad 5, Knut E.A. Lundin 6, Torbjørn Omland 3,4, Eivind Ness-Jensen 1

Affiliations

1 Norwegian University of Science and Technology (NTNU), HUNT Research Centre, Levanger, Norway

2 Nord-Trøndelag Hospital Trust, Namsos, Norway

3 K. G. Jebsen Center for Cardiac Biomarkers, University of Oslo, Oslo, Norway

4 University of Oslo, Institute of Clinical Medicine, Oslo, Norway

5 St. Olavs Hospital Trondheim, NTNU, Trondheim, Norway

6 Norwegian Coeliac Disease Research Centre, University of Oslo and Oslo University Hospital, Oslo, Norway

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Coeliac disease (CeD) is a chronic immune-mediated enteropathy driven by dietary gluten proteins. Previous studies have indicated an increased risk of cardiovascular disease (CVD) in individuals with CeD [1-3]. However, results are inconsistent and specific guidelines on the management of CVD risk and comorbidities for individuals with CeD do not exist. In this study, we aimed to compare the distribution of traditional CVD risk factors in CeD patients and non-CeD controls from a population-based cohort.

Aims & Methods

We performed a CeD screening of 54,541 serum samples by anti-transglutaminase 2 immunoglobulin A and G serology from in total 56,042 adult participants in the fourth wave of the Norwegian Trøndelag Health Study (HUNT4) [4]. All seropositive participants were invited to upper endoscopy with duodenal biopsies to confirm a CeD diagnosis. Seronegative participants with previously diagnosed CeD were identified by linkage to hospital records and the Norwegian Patient Registry. We calculated SCORE2 and SCORE2-OP as predictors for 10-year risk of first-onset CVD [5, 6]. The groups “no CeD”, previously diagnosed CeD (“known CeD”) and CeD diagnosed in HUNT4 (“new CeD”), as well as “CeD” (known + new cases) were examined in this study. To compare group characteristics, we used the Wilcoxon rank sum test. Associations between groups and SCORE2(-OP) were assessed using ordinal logistic regression analysis.

Results

468 (0.80%) individuals received a CeD diagnosis in HUNT4, while 309 (0.57%) seronegative individuals had known CeD. Individuals with newly diagnosed CeD were younger, better educated, and had lower blood lipids compared to controls. Individuals with CeD smoked significantly less, had lower BMI and waist-hip-ratio, glycated hemoglobin levels, serum creatinine, and hsCRP levels compared to controls without CeD (n=52,438; p<0.05 for all variables mentioned, see table). We found a significantly lower SCORE2 for CeD cases (n=589) compared to controls (n=39,747; p<0.05). Adjustment for alcohol consumption did not affect group characteristics. A significantly lower SCORE2 was observed in CeD cases also after adjustment for level of education (OR .84, 95% CI .72-.98), high sensitivity C-reactive protein (hsCRP) and serum creatinine (OR .85, 95% CI .78-.99), but not for the combination of all three variables (OR .90, 95% CI .76-1.05).

	No CeD (n=52,438)	New CeD (n=468)	Known CeD (n=309)
Age, median years (range)	56 (20-103)	53 (20-92)	57 (20-92)
Female sex, percent	55	54	72
Smoking history, median pack years (range)	9.5 (0-154)	6.1 (0-38)	6.8 (0-32)
Alcohol intake, median g/week (range)	23.8 (0-1315)	23.8 (0-162)	20.8 (0-168)
BMI median kg/m2 (range)	26.7 (13.6-64.2)	25.9 (16.2-42.0)	25.6 (17.1-40.6)
Waist-hip-ratio, median (range)	.95 (.61-1.62)	.94 (.77-1.22)	.93 (.74-1.36)
Serum creatinine, median umol/l (range)	71.6 (14.6-696.7)	68.7 (34.2-536.0)	67.8 (30.4-166.3)
hsCRP, median mg/l (range)	1.2 (.1-160.0)	1.0 (.1-64.9)	1.0 (.1-26.3)
HbA1c, median in percent (range)	5.2 (3.2-15.2)	5.2 (4.5-7.8)	5.2 (4.5-7.6)

Conclusion

Individuals with CeD appear to have a lower cardiovascular risk based on traditional risk factors like smoking habits, body fat, diabetes, renal function and inflammation compared to control individuals without CeD. In line with that, SCORE2 and SCORE2-OP as predictors for 10-year risk of first-onset CVD were lower in individuals with CeD.

References

1. Bathrellou, E., M.D. Kontogianni, and D.B. Panagiotakos, Celiac disease and non-celiac gluten or wheat sensitivity and health in later life: A review. Maturitas, 2018. 112: p. 29-33.
2. Ludvigsson, J.F., et al., Nationwide cohort study of risk of ischemic heart disease in patients with celiac disease. Circulation, 2011. 123(5): p. 483-90.
3. Figtree, G.A., et al., Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data. Lancet, 2021. 397(10279): p. 1085-1094.
4. Asvold, B.O., et al., Cohort Profile Update: The HUNT Study, Norway. Int J Epidemiol, 2023. 52(1): p. e80-e91.
5. SCORE2 working group and ESC Cardiovascular risk collaboration, SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J, 2021. 42(25): p. 2439-2454.
6. SCORE2-OP working group and ESC Cardiovascular risk collaboration, SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. European Heart Journal, 2021. 42(25): p. 2455-2467.

Disclosure

None.

Conference

UEG Week Berlin 2025

Topics

Small Intestine & Nutrition

Submission format

Abstract

Session

Coeliac disease: Mechanism and disease association (Posters)

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

BUDESONIDE ORODISPERSIBLE TABLETS REDUCE ESOPHAGEAL STRICTURE FORMATION AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION: RESULTS OF A MULTINATIONAL, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL

Arjun D. Koch

The weird, wonderful , unusual and unexpected in gastroenterology

Charles Murray

CARDIOVASCULAR RISK IN INDIVIDUALS WITH COELIAC DISEASE IN THE TRØNDELAG HEALTH STUDY (HUNT4)

Eivind Ness-Jensen

FATIGUE IN CELIAC DISEASE – A PROSPECTIVE STUDY ON THE LONG-TERM EFFECT OF A GLUTEN FREE DIET

Tore Grimstad

ANXIETY AND DEPRESSION IN INDIVIDUALS WITH UNTREATED CELIAC DISEASE

Eivind Ness-Jensen

RESURFACE OF ANTI-GLIADIN ANTIBODIES IN CELIAC DISEASE? A PROGNOSTIC TOOL FOR ASSESSING MUCOSAL RECOVERY IN CELIAC DISEASE

Anca-Victorita Trifan

Fatigue instrument	Visit 1	Visit 2	Visit 3	Change from Visit 1 to Visit 3 (95% CI)	P-value Visit 1 vs. Visit 3	P-values across three time points (Visit 1, 2 and 3)
FSS	3.7 (2.2-5.0)	1.9 (1.5 - 3.3)	2.3 (1.3 - 4.2)	-0.5 (-1.2 – -0.2	0.012	<0.001
fVAS	45 (16.5-68.5)	15 (9.0 - 41.0)	21 (4.0 - 56.0)	-10 (-23.0 – -3.0)	0.003	0.001
SF-36vs (inverted)	65.0 (40.0-77.5)	30.0 (25.0 - 47.5)	45.0 (30.0 - 70.0)	-5.0 (-10 – 0)	0.006	<0.001